"18F-FDG PET/CT shows vascular 18F-FDG uptake in affected arteries, particularly affected large vessels 26,27. According to one study, the most common arteries where this uptake is demonstrated include 26:"
"18F-FDG PET/CT shows vascular 18F-FDG uptake in affected arteries, particularly affected large vessels 26,27. According to one study, the most common arteries where this uptake is demonstrated include 26:"
"18F-FDG PET/CT has a similar sensitivity and specificity to MRI for the diagnosis of giant cell arteritis 32. There may also be concurrent uptake in a pattern consistent with polymyalgia rheumatica, such as within the shoulders and hips 28."
"18F-FDG PET/CT shows vascular 18F-FDG uptake in affected arteries, particularly affected large vessels 26,27. According to one study, the most common arteries where this uptake is demonstrated include 26:"
"18F-FDG PET/CT has a similar sensitivity and specificity to MRI for the diagnosis of giant cell arteritis 32. There may also be concurrent uptake in a pattern consistent with polymyalgia rheumatica, such as within the shoulders and hips 28."
"The first description of giant cell arteritis was provided by Sir Jonathan Hutchison (1828-1913), British physician, in 1890 36. A subsequent seminal publication of two cases was made by Byarad Taylor Horton (1895-1980), American physician, and colleagues in 1934 36."
"Historically, giant cell arteritis was also known as temporal arteritis or cranial arteritis, given its propensity to involve the extracranial external carotid artery branches such as the superficial temporal artery. Importantly, other large vessels, such as the aorta and upper limb arteries, may also be involved, sometimes without cranial involvement. Thus, the term giant cell arteritis is preferred 30."
"Historically, giant cell arteritis was also known as temporal arteritis or cranial arteritis, given its propensity to involve the extracranial external carotid artery branches such as the superficial temporal artery. Importantly, other large vessels, such as the aorta and upper limb arteries, may also be involved, sometimes without cranial involvement. Thus, the term giant cell arteritis is preferred 30."
"upadacitinib (JAK inhibitor)"
Expected headings
"Markers"
"Associations"
"Complications"
"It typically affects patients older than 50 years, with a peak incidence between the ages of 70 and 80 years 3. There is a recognised female predilection (F:M 2:1) 30."
"systemic symptoms (e.g. fever, fatigue, weight loss)"
"permanent vision loss (e.g. due to arteritic anterior ischaemic optic neuropathy, central retinal artery occlusion, cilioretinal artery occlusion, paracentral acute middle maculopathy (PAMM), ischaemic stroke, etc.)"
"corticosteroids (e.g. prednisolone)"
"reversible under corticosteroid treatment; this is reflected in the normalisation of the sonographic features"